BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, Konar A, Chawla YK, Jain RK, Nanda V, Kumar A, Hissar S, Lavate P, Lahoti D, National Collaborative Group on Hepatitis B I. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol. 2007;102:96-104. [PMID: 17266689 DOI: 10.1111/j.1572-0241.2006.01006.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Huang YW, Chayama K, Kao JH, Yang SS. Detectability and clinical significance of serum hepatitis B virus ribonucleic acid. Hepatobiliary Surg Nutr 2015;4:197-202. [PMID: 26151059 DOI: 10.3978/j.issn.2304-3881.2014.11.08] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
2 Cox N, Tillmann H. Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs 2011;16:713-29. [PMID: 22195605 DOI: 10.1517/14728214.2011.646260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
3 Berraondo P, Di Scala M, Korolowicz K, Thampi LM, Otano I, Suarez L, Fioravanti J, Aranda F, Ardaiz N, Yang J. Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. J Hepatol. 2015;63:329-336. [PMID: 25772035 DOI: 10.1016/j.jhep.2015.02.048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
4 Wong GL, Wong VW, Chan HL. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. J Viral Hepat 2014;21:825-34. [PMID: 25402543 DOI: 10.1111/jvh.12341] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
5 Su TH, Liu CJ. Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut Liver 2017;11:590-603. [PMID: 28494575 DOI: 10.5009/gnl16215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
6 Moucari R, Boyer N, Ripault M, Castelnau C, Mackiewicz V, Dauvergne A, Valla D, Vidaud M, Chanoine MN, Marcellin P. Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients: Sequential therapy for HBeAg (−) patients. Journal of Viral Hepatitis 2011;18:580-6. [DOI: 10.1111/j.1365-2893.2010.01332.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
7 Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Fujii H, Uchida-Kobayashi S, Fukunishi S, Tsuda Y, Higuchi K, Saito M, Enomoto H, Kawada N. Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B. Hepatol Res 2018;48:459-68. [PMID: 29314465 DOI: 10.1111/hepr.13050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Reference Citation Analysis]
9 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 644] [Article Influence: 48.9] [Reference Citation Analysis]
10 Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver International 2010;30:657-68. [DOI: 10.1111/j.1478-3231.2010.02207.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ray G. Current Scenario of Hepatitis B and Its Treatment in India. J Clin Transl Hepatol 2017;5:277-96. [PMID: 28936409 DOI: 10.14218/JCTH.2017.00024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
12 Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018;117:588-597. [PMID: 29456079 DOI: 10.1016/j.jfma.2017.12.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
13 Liu YH, Wu T, Sun N, Wang GL, Yuan JZ, Dai YR, Zhou XH. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study. J Huazhong Univ Sci Technolog Med Sci 2014;34:542-7. [PMID: 25135724 DOI: 10.1007/s11596-014-1312-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
14 Rijckborst V, Sonneveld MJ, Janssen HL. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther. 2011;33:501-513. [PMID: 21198707 DOI: 10.1111/j.1365-2036.2010.04555.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
15 Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol Int 2008;2:140-6. [PMID: 19669298 DOI: 10.1007/s12072-008-9046-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
16 Huang R, Hao Y, Zhang J, Wu C. Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis. Hepatol Res 2013;43:1040-51. [PMID: 23356962 DOI: 10.1111/hepr.12058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014;61:777-84. [PMID: 24915612 DOI: 10.1016/j.jhep.2014.05.044] [Cited by in Crossref: 136] [Cited by in F6Publishing: 111] [Article Influence: 19.4] [Reference Citation Analysis]
18 Rijckborst V, Janssen HL. The Role of Interferon in Hepatitis B Therapy. Curr Hepat Rep 2010;9:231-8. [PMID: 20949114 DOI: 10.1007/s11901-010-0055-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
19 Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol. 2013;48:999-1005. [PMID: 23338486 DOI: 10.1007/s00535-012-0742-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kumar M, Sarin SK. Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Aliment Pharmacol Ther. 2008;27:1187-1209. [PMID: 18373730 DOI: 10.1111/j.1365-2036.2008.03695.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
21 Cannizzo ES, Tincati C, Binda F, Ronzi P, Cazzaniga FA, Antinori S, d'Arminio Monforte A, Marchetti G, Milazzo L. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study. J Viral Hepat 2018;25:381-90. [PMID: 29091327 DOI: 10.1111/jvh.12820] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
22 van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat 2019;26:109-17. [PMID: 30187612 DOI: 10.1111/jvh.12997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
23 Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008;23:1182-1192. [PMID: 18637060 DOI: 10.1111/j.1440-1746.2008.05400.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
24 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 647] [Article Influence: 77.2] [Reference Citation Analysis]
25 Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Hayashi T, Kohmoto MT, Jomura H, Morikawa H, Murakami Y, Shiomi S. Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. J Interferon Cytokine Res. 2015;35:613-620. [PMID: 25884105 DOI: 10.1089/jir.2014.0234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
26 Wang H, Wu D, Wang X, Chen G, Zhang Y, Yan W, Luo X, Han M, Ning Q. Hepatitis B virus surface protein-induced hPIAS1 transcription requires TAL1, E47, MYOG, NFI, and MAPK signal pathways. Biological Chemistry 2016;397:1173-85. [DOI: 10.1515/hsz-2015-0290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
27 Lo AO, Wong GL. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol. 2014;8:607-622. [PMID: 24787673 DOI: 10.1586/17474124.2014.909724] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
28 Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
29 Buey LG, Mateos FG, Oteroa RM. Interferón en la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 2008;26:19-31. [DOI: 10.1016/s0213-005x(08)76516-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
30 Vyas AK, Jindal A, Hissar S, Ramakrishna G, Trehanpati N. Immune balance in Hepatitis B Infection: Present and Future Therapies. Scand J Immunol 2017;86:4-14. [PMID: 28387980 DOI: 10.1111/sji.12553] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Niro GA, Fontana R, Gioffreda D, Fiorella S, Accadia L, Iacobellis A, Caruso N, Conoscitore P, Andriulli A. Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study. Dig Liver Dis. 2007;39:857-863. [PMID: 17652045 DOI: 10.1016/j.dld.2007.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
32 Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-78. [PMID: 19669301 DOI: 10.1007/s12072-008-9061-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
33 Fairman J, Liu KH, Menne S. Prevention of liver tumor formation in woodchucks with established hepatocellular carcinoma by treatment with cationic liposome-DNA complexes. BMC Cancer. 2017;17:172. [PMID: 28264666 DOI: 10.1186/s12885-017-3163-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
34 Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
35 Chevaliez S, Pawlotsky JM. Interferons and their use in persistent viral infections. Handb Exp Pharmacol 2009;:203-41. [PMID: 19048202 DOI: 10.1007/978-3-540-79086-0_8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
36 Lu J, Zhang S, Liu Y, Du X, Ren S, Zhang H, Ma L, Chen Y, Chen X, Shen C. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. Liver Int 2015;35:1692-9. [DOI: 10.1111/liv.12753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
37 You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol. 2014;20:13293-13305. [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
38 Chen X, Qian Y, Yan F, Tu J, Yang X, Xing Y, Chen Z. 5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells. Eur J Pharmacol 2013;721:86-95. [PMID: 24099962 DOI: 10.1016/j.ejphar.2013.09.050] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
39 Xie Q, Zhou H, Bai X, Wu S, Chen J, Sheng J, Xie Y, Chen C, Chan HL, Zhao M. A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. Clinical Infectious Diseases 2014;59:1714-23. [DOI: 10.1093/cid/ciu702] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
40 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 950] [Article Influence: 179.3] [Reference Citation Analysis]
41 Hofmann WP, Soriano V, Zeuzem S. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Handb Exp Pharmacol 2009;:321-46. [PMID: 19048206 DOI: 10.1007/978-3-540-79086-0_12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
42 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-S19. [PMID: 18304680 DOI: 10.1016/j.jhep.2008.01.011] [Cited by in Crossref: 107] [Cited by in F6Publishing: 103] [Article Influence: 8.2] [Reference Citation Analysis]
43 Boglione L, D'avolio A, Cariti G, Milia MG, Simiele M, De Nicolò A, Ghisetti V, Di Perri G. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 2013;20:e11-9. [DOI: 10.1111/jvh.12018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
44 Viganò M, Mangia G, Lampertico P. Results of Treatment of Chronic Hepatitis B with Pegylated Interferon. Clinics in Liver Disease 2013;17:425-43. [DOI: 10.1016/j.cld.2013.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
45 Kishida Y, Haruna Y, Naitoh M, Katayama K, Kashiwagi T. Multiple Cytokine Profiling of the Therapeutic Responses to Ribavirin and Pegylated Interferon-α2b Using an “Induction” Approach With Natural Interferon-β in Difficult-to-Treat Chronic Hepatitis C. Journal of Interferon & Cytokine Research 2009;29:353-68. [DOI: 10.1089/jir.2008.0110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
46 Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections: Facing antiviral drug resistance. Journal of Gastroenterology and Hepatology 2012;27:1432-40. [DOI: 10.1111/j.1440-1746.2012.07198.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]